N-[(2S,3R)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: N-[(2S,3R)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide
• 化学式: C₂₇H₂₅ClF₃N₃O₂
• 分子量: 516.0
• InChiKey: QLYKJCMUNUWAGO-SBUREZEXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  75
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities
  申请人：UNIVERSITAT POMPEU FABRA

  公开号：US20160067235A1

  公开（公告）日：2016-03-10

  The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
• US9662320B2
  申请人：——

  公开号：US9662320B2

  公开（公告）日：2017-05-30